The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New progress in radioactive iodine therapy of differentiated thyroid carcinoma

doi:10.3969/j.issn.1007-3969.2016.01.001

Abstract

Abstract: Recently, the morbidity of differentiated thyroid carcinoma (DTC) has increased annually. American Thyroid Association (ATA) published the management guidelines for patients with thyroid nodules and DTC in 2006 in order to standardize their management. The ATA guidelines was updated for the first time in 2009 and its renewed version was completed in 2015 based on the considerable progress that had been made in the fields such as diagnostic assessment and management of thyroid nodules, surgery and radioactive iodine therapy for DTC in recent years. This article tried to interpret the updated contents about radioactive iodine therapy for DTC in 2015 version of the guidelines.

Key words: 2015 version of American Thyroid Association Guidelines, Differentiated thyroid carcinoma, Radioactive iodine therapy, Research progress

LIN Yansong, LI Jiao. The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New progress in radioactive iodine therapy of differentiated thyroid carcinoma[J]. China Oncology, 2016, 26(1): 1-12.

[1]	QIAN Bin, CHEN Haiquan. Important progress in surgical treatment of lung cancer in 2023 [J]. China Oncology, 2024, 34(4): 335-339.
[2]	ZHANG Qi, XIU Bingqiu, WU Jiong. Progress of important clinical research of breast cancer in China in 2023 [J]. China Oncology, 2024, 34(2): 135-142.
[3]	ZHANG Siyuan, JIANG Zefei. Important research progress in clinical practice for advanced breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 143-150.
[4]	ZHANG Huiqiang, JIANG Zefei. Key clinical studies on changing clinical practice of advanced breast cancer in 2022 [J]. China Oncology, 2023, 33(2): 110-116.
[5]	Expert Committee of Nuclear Medicine, Chinese society of Clinical Oncology, Expert Committee of Thyroid Cancer, Chinese society of Clinical Oncology, Committee of Thyroid Disease Society, China International Exchange and Promotive Association for Medical and Health Care, Committee of Thyroid Disease Prevention and Treatment Society, China Population Culture Promotion Association. Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition) [J]. China Oncology, 2022, 32(5): 451-468.
[6]	QI Mengfang, TIAN Tian, HUANG Rui. Clinicopathological characteristics and ¹³¹I treatment of differentiated thyroid carcinoma in children and adolescents of different age groups [J]. China Oncology, 2022, 32(5): 404-409.
[7]	LI Yujie, CHEN Hao. Potential of targeting TROP2 in the treatment of pancreatic cancer [J]. China Oncology, 2022, 32(3): 268-273.
[8]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[9]	MU Zhuanzhuan , LI Zheng , ZHANG Xin , LIN Yansong . The effect of empiric ¹³¹ I therapy in papillary thyroid cancer patients with pulmonary metastasis [J]. China Oncology, 2020, 30(12): 991-995.
[10]	ZHANG Na, LIN Yansong, LIANG Jun. The clinical significance of thyroglobulin antibody measurement in 131I therapy of differentiated thyroid carcinoma [J]. China Oncology, 2019, 29(6): 452-456.
[11]	LU Chenghui, LI Jiao, LIU Xinfeng, WANG Guoqiang, WANG Zenghua, WANG Xufu. Clinical outcome after ¹³¹I treatment in differentiated thyroid cancer with negative stimulated thyroglobulin and lymph node metastasis [J]. China Oncology, 2019, 29(6): 429-433.
[12]	SUI Huimin, LIU Jierui, WANG Tong, ZHU Zhaohui, LIN Yansong. Clinicopathological risk factors for distant metastasis of differentiated thyroid carcinoma in children and adolescents [J]. China Oncology, 2019, 29(6): 423-428.
[13]	YANG Ke, ZHENG Rong, LIN Yansong. The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress [J]. China Oncology, 2019, 29(6): 401-411.
[14]	LIU Jierui, LIANG Jun, LIN Yansong. Relationship between preablative stimulated thyroglobulin and the excellent response in differentiated thyroid carcinoma [J]. China Oncology, 2019, 29(2): 125-130.
[15]	ZHANG Teng, HU Houyang, BAI Qinghua, et al. Effect of lymphocytic thyroiditis on response of differentiated thyroid cancer patients after ¹³¹I therapy [J]. China Oncology, 2018, 28(6): 419-423.

The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New progress in radioactive iodine therapy of differentiated thyroid carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments